Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib,cyclophosphamide,and dexamethasone  

作　　者：陈苗 CHEN Miao(Dept Hematol,PUMC&CAMS,Beijing 100730)

机构地区：[1]Dept Hematol,PUMC&CAMS,Beijing 100730

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第1期56-56,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To.analyze the efficacy of second-line regimens and prognostic factors in patients with firstrelapsed multiple myeloma (MM) treated with bortezomib,cyclophosphamide,and dexamethasone(BCD).Methods Clinical data were collected in firstrelapsed MM patients after BCD treatment from three tertiary hospitals in north China from July 2009 to October 2022.

关 键 词：regimen PATIENTS RELAPSE 

分 类 号：R733.3[医药卫生—肿瘤]